|Bid||19.00 x 800|
|Ask||23.30 x 800|
|Day's Range||20.92 - 21.34|
|52 Week Range||15.04 - 25.43|
|Beta (3Y Monthly)||1.00|
|PE Ratio (TTM)||432.86|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.75|
Amphastar Pharmaceuticals, Inc. (AMPH) announced today that Jason Shandell, President and Bill Peters, CFO, will be presenting at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019 at 3:40 p.m. Pacific Time, Las Vegas, NV. This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com . Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
Amphastar (AMPH) delivered earnings and revenue surprises of 233.33% and 6.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Rancho Cucamonga, California-based company said it had profit of 2 cents. Earnings, adjusted for non-recurring costs, came to 10 cents per share. The results topped Wall Street ...
RANCHO CUCAMONGA, Calif., May 09, 2019 -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March.
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
Amphastar Pharmaceuticals, Inc. (AMPH) announced that the Company will release results for its first quarter of 2019 ended March 31, 2019, after the market closes on Thursday, May 9, 2019, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (877) 881-2595, or (315) 625-3083 for international callers, five minutes before the conference. The passcode for the conference call is 8047099.
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A look at the shareholders of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often de...
HENDERSON, NV / ACCESSWIRE / April 15, 2019 / No industry is growing faster than the global cannabis market. One small-cap stock in the space beginning to gain investor favor is THC Therapeutics, Inc. ...
After all, the South San Francisco drug developer won two Food and Drug Administration approvals last year and, after slow sales of one of those drugs, it has focused on fixing manufacturing issues, nabbing European regulatory approval and getting hospitals to use the second drug, called Andexxa. At the same time, Portola (NASDAQ: PTLA) is moving forward with mid-stage studies of an experimental blood cancer drug. "Any biotech company can get bought," said Garland, who took over in October after the departure of Bill Lis, "but that's not where we spend our time." Yet with Portola's infrastructure built out, it is more attractive to larger companies that want the potential of Andexxa, the company's first-in-class antidote to blood-thinning drugs when a patient has uncontrolled bleeding.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 18) AstraZeneca plc (NYSE: AZN )(received orphan drug ...
Amphastar Pharmaceuticals, Inc., (AMPH) announced that the U.S. Food and Drug Administration (FDA) granted approval of its Abbreviated New Drug Application (“ANDA”) for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial (MDV). The company currently manufactures and distributes Enoxaparin Sodium Injection in prefilled syringe form and this approval of the Multiple Dose Vial allows the company to begin offering the full line of Enoxaparin products. Amphastar’s newly approved product was determined by the FDA to be therapeutically equivalent to Lovenox® (Enoxaparin Sodium Injection) MDV sold in the United States by Sanofi-Aventis.
Amphastar Pharmaceuticals Inc is a specialty pharmaceutical company engaged in developing, manufacturing, marketing and selling generic and proprietary injectable & inhalation products. Warning! GuruFocus has detected 3 Warning Signs with AMPH. For the last quarter Amphastar Pharmaceuticals Inc reported a revenue of $89.7 million, compared with the revenue of $60.40 million during the same period a year ago.
Amphastar Pharmaceuticals plunged Wednesday despite its better-than-expected fourth-quarter earnings on a lack of key drug approvals expected in 2019. An analyst called for a pause in 2019.
If you own shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...
Amphastar (AMPH) delivered earnings and revenue surprises of 30.00% and 18.85%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Rancho Cucamonga, California-based company said it had profit of 4 cents. Earnings, adjusted for non-recurring costs, came to 13 cents per share. The results exceeded Wall Street ...
Reports Net Revenues of $89.7 Million for the Three Months Ended December 31, 2018 RANCHO CUCAMONGA, Calif., March 12, 2019 -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH).